OPTIMIZATION OF ERADICATION THERAPY IN PATIENTS WITH ANTIBIOTIC-RESISTANT HELICOBACTER PYLORI INFECTION: COMPARATIVE EFFICACY OF CURRENT REGIMENS

Authors

  • Tolibov Farrux Farhodivich Asia International University, Bukhara, Uzbekistan

Keywords:

Helicobacter pylori, antibiotic resistance, clarithromycin, bismuth quadruple therapy, vonoprazan, eradication therapy.

Abstract

Helicobacter pylori (H. pylori) infection is one of the most widespread chronic bacterial infections in the world; in 2015 the number of infected individuals was estimated at approximately 4.4 billion [1]. H. pylori is the principal etiological factor of chronic gastritis, peptic ulcer disease, MALT lymphoma and gastric adenocarcinoma; therefore, its effective eradication is regarded as a means of primary prevention of gastric cancer [2].

References

1.Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.

2.Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–62.

3.Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372–82.e17.

4.Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815–22.

5.Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40–54.

6.Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119(9):1730–53.

7.Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831–41.

8.Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systematic review and meta-analysis. Helicobacter. 2019;24(2):e12565.

9.Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24(2):e12570.

10.Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19.

Downloads

Published

2026-10-08

Conference Proceedings Volume

Section

Articles

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.